Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | JAX:10000003 |
Name | Advanced Solid Tumor |
Definition | A malignant solid tumor |
Source | Genomenon (a custom term added that does not correspond to an existing term in the disease ontology) |
Alt Ids | |
Path | Advanced Solid Tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA mutant | CUDC-907 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA wild-type | PX-866 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | PX-866 | Advanced Solid Tumor | sensitive | detail... |
TP53 mutant | Bevacizumab | Advanced Solid Tumor | sensitive | detail... |
FGFR2 act mut | Zoligratinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Taselisib | Advanced Solid Tumor | conflicting | detail... |
PIK3CA mutant | M2698 | Advanced Solid Tumor | sensitive | detail... |
TP53 positive | MVAp53 | Advanced Solid Tumor | sensitive | detail... |
BRAF V600E | PLX8394 | Advanced Solid Tumor | sensitive | detail... |
BRAF L597R | Trametinib | Advanced Solid Tumor | sensitive | detail... |
BRAF L597R | Vemurafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF L597S | Vemurafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF L597S | Trametinib | Advanced Solid Tumor | sensitive | detail... |
BRAF K601E | Trametinib | Advanced Solid Tumor | sensitive | detail... |
BRAF K601E | Vemurafenib | Advanced Solid Tumor | conflicting | detail... |
BRAF mutant | Dabrafenib | Advanced Solid Tumor | sensitive | detail... |
TP53 wild-type | Pazopanib + Vorinostat | Advanced Solid Tumor | decreased response | detail... |
RET mutant | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
BRAF act mut | Binimetinib + Encorafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF act mut | PLX8394 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 R248C | Vofatamab | Advanced Solid Tumor | sensitive | detail... |
FGFR3 S249C | Vofatamab | Advanced Solid Tumor | sensitive | detail... |
FGFR3 G372C | Vofatamab | Advanced Solid Tumor | sensitive | detail... |
FGFR3 Y375C | Vofatamab | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K652E | Vofatamab | Advanced Solid Tumor | sensitive | detail... |
FGFR3 mutant | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
TP53 loss | Adavosertib | Advanced Solid Tumor | sensitive | detail... |
PTEN negative | Talazoparib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | XL147 | Advanced Solid Tumor | sensitive | detail... |
RET G691S | Dovitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 act mut | Zoligratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 act mut | Zoligratinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | BAY1125976 | Advanced Solid Tumor | sensitive | detail... |
PTEN loss | BAY1125976 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Everolimus | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E542K | Sirolimus | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Metformin | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E545K | Sirolimus | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E545K | Alpelisib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Onatasertib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Ipatasertib + Paclitaxel | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Afuresertib | Advanced Solid Tumor | sensitive | detail... |
RAD51D loss | Olaparib | Advanced Solid Tumor | sensitive | detail... |
JAK3 V722I | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA C420R | Sirolimus | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Alpelisib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Carboxyamidotriazole Orotate | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Serabelisib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | VS-5584 | Advanced Solid Tumor | sensitive | detail... |
RB1 positive | Ribociclib | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS G12V | Cetuximab | Advanced Solid Tumor | resistant | detail... |
HRAS G12V | Panitumumab | Advanced Solid Tumor | resistant | detail... |
FLT3 D835Y | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
RET S891A | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
RET M918T | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
RET C634R | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | Obatoclax | Advanced Solid Tumor | sensitive | detail... |
NRAS mutant | Obatoclax | Advanced Solid Tumor | sensitive | detail... |
RET C634R | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET V804L | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET V804M | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Sapanisertib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK S1206Y | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
RET V804M | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
FLT3 Y572C | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
FLT3 S451F | Midostaurin | Advanced Solid Tumor | decreased response | detail... |
FLT3 V592G | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
FLT3 R834Q | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
FLT3 R834Q | PD98059 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA M1043V | Sirolimus | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | BAY1082439 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D839G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 Y842C | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 amp | Ponatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
SMARCA4 loss | N/A | Advanced Solid Tumor | not applicable | detail... |
KIT V560D | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Dasatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560G | Nilotinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N550K | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N550S | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 N550H | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 V565I | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 E566G | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 L618M | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 K660E | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 I548V | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 M538I | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 M536I | Dovitinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 N550H | PD173074 | Advanced Solid Tumor | resistant | detail... |
FGFR2 E566G | PD173074 | Advanced Solid Tumor | resistant | detail... |
FGFR2 M536I | PD173074 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 M538I | PD173074 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 I548V | PD173074 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 N550S | PD173074 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 L618M | PD173074 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 V565I | Ponatinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 M538I | Ponatinib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 K660E | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 M536I | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 I548V | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N550H | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N550K | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N550S | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 E566G | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 S267_D273dup | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290_I291delinsC | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 S267_D273dup | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290_I291delinsC | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | A-443654 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E545K | A66 | Advanced Solid Tumor | resistant | detail... |
PIK3CA H1047R | A66 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | AT-7867 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Taselisib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Alectinib | Advanced Solid Tumor | sensitive | detail... |
ARID1B dec exp | Cisplatin | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK C1156Y | Alectinib | Advanced Solid Tumor | sensitive | detail... |
RET Y806C | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET A883F | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET Y791F | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET E768D | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET L790F | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET D898V | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET M918T | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET C634Y | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET E884K | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
RET S891A | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
FLT3 wild-type | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
FGFR2 S252W | Dovitinib | Advanced Solid Tumor | conflicting | detail... |
FGFR2 N550K | PD173074 | Advanced Solid Tumor | resistant | detail... |
FGFR2 V565I | PD173074 | Advanced Solid Tumor | resistant | detail... |
FGFR2 L618M | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | PD173074 | Advanced Solid Tumor | decreased response | detail... |
PIK3CA mutant | Bevacizumab + Pegylated liposomal doxorubicin + Temsirolimus | Advanced Solid Tumor | sensitive | detail... |
FBXW7 inact mut | Entinostat | Advanced Solid Tumor | sensitive | detail... |
FBXW7 inact mut | Docetaxel | Advanced Solid Tumor | resistant | detail... |
FBXW7 inact mut | Belinostat | Advanced Solid Tumor | sensitive | detail... |
FBXW7 inact mut | REC-2282 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171T | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK V1180L | TAE684 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | TAE684 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | Brigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | ASP3026 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | ASP3026 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | ASP3026 | Advanced Solid Tumor | resistant | detail... |
TP53 mutant | Pazopanib + Vorinostat | Advanced Solid Tumor | sensitive | detail... |
RET E768D | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET L790F | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET Y791F | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET S891A | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET M918T | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET A883F | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET V804L | Vandetanib | Advanced Solid Tumor | resistant | detail... |
RET V804M | Vandetanib | Advanced Solid Tumor | resistant | detail... |
RET C634R | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
RET C634R RET V804G | Vandetanib | Advanced Solid Tumor | sensitive | detail... |
FGFR1 act mut | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 act mut | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 act mut | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR1 act mut | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 act mut | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 act mut | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR1 act mut | Cediranib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 act mut | Cediranib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 act mut | Cediranib | Advanced Solid Tumor | decreased response | detail... |
FGFR1 act mut | Nintedanib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 act mut | Nintedanib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 act mut | Nintedanib | Advanced Solid Tumor | decreased response | detail... |
FGFR2 act mut | Brivanib | Advanced Solid Tumor | decreased response | detail... |
FGFR1 act mut | Brivanib | Advanced Solid Tumor | no benefit | detail... |
FGFR3 act mut | Brivanib | Advanced Solid Tumor | no benefit | detail... |
KIT D816V | Ponatinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins | Cabozantinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT D816V | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT D816V | Nilotinib | Advanced Solid Tumor | decreased response | detail... |
KIT D816V | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT D816V | Cabozantinib | Advanced Solid Tumor | resistant | detail... |
KIT D816H | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT D816V | Quizartinib | Advanced Solid Tumor | resistant | detail... |
RET rearrange | RXDX-105 | Advanced Solid Tumor | sensitive | detail... |
PTEN del | GSK2636771 | Advanced Solid Tumor | no benefit | detail... |
PIK3CA mutant | AZD8835 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Uprosertib | Advanced Solid Tumor | predicted - sensitive | detail... |
RB1 loss | Palbociclib | Advanced Solid Tumor | no benefit | detail... |
TP53 R175H | ReACp53 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 wild-type | AZ6089 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 over exp | LY2874455 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | PD98059 | Advanced Solid Tumor | sensitive | detail... |
FGFR1 act mut | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 act mut | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 act mut | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 fusion | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V561M | FIIN-1 | Advanced Solid Tumor | sensitive | detail... |
FGFR1 fusion | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA Q546K | Trametinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA N345K | Trametinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA H1047R | Trametinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA G1049R | Trametinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E545K | Trametinib | Advanced Solid Tumor | sensitive | detail... |
KIT H697Y | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT H697Y | Imatinib | Advanced Solid Tumor | decreased response | detail... |
KIT V560del | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560del | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
PTEN del | Onatasertib | Advanced Solid Tumor | sensitive | detail... |
CSF3R T640N | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R T618I | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins | Pexidartinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 F691L | Pexidartinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 D835V | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835Y | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835V | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835F | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 Y842H | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 M664I | Pexidartinib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 M664I FLT3 F691L | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N676S | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N676S FLT3 F691L | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D698N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D698N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 R834Q | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 R834Q | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835E | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D835E | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D835G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D835H | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835H | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D835N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D835N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D835Y | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D839A | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D839A | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D839G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D839H | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 D839N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 D839N | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N841K | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 N841K | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 Y842C | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 Y842H | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 Y842S | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 Y842S | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 R845G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 R845G | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 G846R | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L FLT3 G846R | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
PTEN dec exp | GSK2636771 | Advanced Solid Tumor | sensitive | detail... |
TP53 R248Q | Ganetespib | Advanced Solid Tumor | sensitive | detail... |
TP53 R175H | Alvespimycin + Vorinostat | Advanced Solid Tumor | sensitive | detail... |
FLT3 D835Y | Pexidartinib | Advanced Solid Tumor | resistant | detail... |
PTEN loss | SAR260301 | Advanced Solid Tumor | no benefit | detail... |
RET C634Y | HG-6-63-01 | Advanced Solid Tumor | sensitive | detail... |
RET C634Y | XMD15-44 | Advanced Solid Tumor | sensitive | detail... |
RET C634Y | ALW-II-41-27 | Advanced Solid Tumor | sensitive | detail... |
RET M918T | HG-6-63-01 | Advanced Solid Tumor | sensitive | detail... |
RET M918T | XMD15-44 | Advanced Solid Tumor | sensitive | detail... |
RET M918T | ALW-II-41-27 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA mutant | Apitolisib | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA act mut | GSK1059615 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171S | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S | Ceritinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK I1171S | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S | Brigatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK I1171S | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S | AZD3463 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174L | Crizotinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK F1174L | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174L | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174L | Brigatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK F1174L | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174L | AZD3463 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK R1192P | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK R1192P | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK R1192P | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK R1192P | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK R1192P | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK R1192P | AZD3463 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151M | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151M | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151M | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151M | AZD3463 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151M | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK T1151M | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1269A | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK G1269A | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1269A | AZD3463 | Advanced Solid Tumor | sensitive | detail... |
ATM loss | YU238259 | Advanced Solid Tumor | sensitive | detail... |
TP53 wild-type | CTX-1 | Advanced Solid Tumor | sensitive | detail... |
TP53 loss | CTX-1 | Advanced Solid Tumor | decreased response | detail... |
TP53 mutant | CTX-1 | Advanced Solid Tumor | sensitive | detail... |
TP53 wild-type | CTX-1 + Nutlin-3a | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Entrectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK G1202R | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Entrectinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK L1198F | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F | Lorlatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y | Ceritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK L1198F | Ceritinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | Brigatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK C1156Y | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK L1198F | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C ALK L1198F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C ALK L1198F | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C | Ceritinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK F1174C ALK L1198F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK F1174C ALK L1198F | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK L1196M | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M ALK L1198F | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK L1198F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK L1198F | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK L1198F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK L1198F | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M | Lorlatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK G1202R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R | Brigatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1269A | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1269A | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F | Ruxolitinib + ZSTK474 | Advanced Solid Tumor | sensitive | detail... |
JAK2 over exp | Ruxolitinib + ZSTK474 | Advanced Solid Tumor | sensitive | detail... |
JAK2 over exp | Pictilisib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK2 V617F | Pictilisib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK2 over exp | Dactolisib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK2 V617F | Dactolisib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK2 V617F | Ruxolitinib + TGX-221 | Advanced Solid Tumor | sensitive | detail... |
JAK2 over exp | Ruxolitinib + TGX-221 | Advanced Solid Tumor | sensitive | detail... |
ALK wild-type | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK G1202R | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK L1196M | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
ALK G1128A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK I1171N | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK F1174L | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK R1192P | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK F1245C | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK R1275Q | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK Y1278S | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
PIK3CA H1047R | Sirolimus | Advanced Solid Tumor | sensitive | detail... |
RET C634R | Pz-1 | Advanced Solid Tumor | sensitive | detail... |
RET M918T | Pz-1 | Advanced Solid Tumor | sensitive | detail... |
RET V804L | Pz-1 | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804M | Pz-1 | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS G12V | Pz-1 | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | XL147 | Advanced Solid Tumor | decreased response | detail... |
KIT act mut | PLX9486 | Advanced Solid Tumor | sensitive | detail... |
ATM inact mut | E7449 | Advanced Solid Tumor | sensitive | detail... |
RAD51C inact mut | E7449 | Advanced Solid Tumor | sensitive | detail... |
ROS1 rearrange | Entrectinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK fusion | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V559D | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560G | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT D816H | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT D820E | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT A829P | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT exon9 | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT exon9 | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT exon9 | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT exon9 | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT P551_K558del | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT P551_K558del | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT P551_K558del | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT P551_K558del | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT P551_E554del | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT T417_D419delinsI | Imatinib | Advanced Solid Tumor | conflicting | detail... |
KIT P551_E554del | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT P551_E554del | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT P551_E554del | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT K558delinsNP | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT K558delinsNP | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT K558delinsNP | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT K558delinsNP | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT V654A | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT V654A | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT V654A | Imatinib | Advanced Solid Tumor | no benefit | detail... |
KIT W557_K558del KIT V654A | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT T670I | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT T670I | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT T670I | Imatinib | Advanced Solid Tumor | no benefit | detail... |
KIT W557_K558del KIT T670I | Regorafenib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT D816H | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D816H | Sunitinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT D816H | Imatinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT D816H | Regorafenib | Advanced Solid Tumor | decreased response | detail... |
BRAF T529I BRAF V600E | SB590885 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V600E | SB590885 | Advanced Solid Tumor | sensitive | detail... |
BRAF T529M BRAF V600E | SB590885 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF T529N BRAF V600E | RAF265 | Advanced Solid Tumor | resistant | detail... |
BRAF T529I BRAF V600E | RAF265 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF T529M BRAF V600E | RAF265 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V600E | RAF265 | Advanced Solid Tumor | sensitive | detail... |
BRAF T529N BRAF V600E | SB590885 | Advanced Solid Tumor | resistant | detail... |
BRAF T529M BRAF V600E | PLX4720 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF T529I BRAF V600E | PLX4720 | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V600E | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
BRAF T529N BRAF V600E | PLX4720 | Advanced Solid Tumor | resistant | detail... |
BRAF T529N BRAF V600E | Sorafenib | Advanced Solid Tumor | conflicting | detail... |
BRAF T529M BRAF V600E | Sorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF T529I BRAF V600E | Sorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF T529N BRAF V600E | CI-1040 | Advanced Solid Tumor | sensitive | detail... |
BRAF T529M BRAF V600E | CI-1040 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF T529I BRAF V600E | CI-1040 | Advanced Solid Tumor | sensitive | detail... |
BRAF V600E | CI-1040 | Advanced Solid Tumor | sensitive | detail... |
KIT W557G | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT Y578C | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557C KIT Y578C | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D816G | Ponatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820A | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D820G | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT N822K | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT A829P | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D816G | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820A | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820G | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT N822K | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT A829P | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D816G | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820A | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820G | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT N822K | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT A829P | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D816G | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT D820A | Regorafenib | Advanced Solid Tumor | conflicting | detail... |
KIT W557_K558del KIT D820G | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT N822K | Regorafenib | Advanced Solid Tumor | conflicting | detail... |
KIT W557_K558del KIT A829P | Regorafenib | Advanced Solid Tumor | conflicting | detail... |
FGFR1 mutant | Pemigatinib | Advanced Solid Tumor | sensitive | detail... |
PTEN dec exp | Pemetrexed Disodium + Sorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
JAK3 V674A | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 L857P | Ruxolitinib | Advanced Solid Tumor | decreased response | detail... |
JAK3 Y100A JAK3 L857P | Ruxolitinib | Advanced Solid Tumor | decreased response | detail... |
JAK3 L857P | NIBR3049 | Advanced Solid Tumor | sensitive | detail... |
JAK3 Y100A JAK3 L857P | NIBR3049 | Advanced Solid Tumor | sensitive | detail... |
JAK3 V674A | NIBR3049 | Advanced Solid Tumor | decreased response | detail... |
JAK3 V674A | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 L857P | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 Y100A JAK3 L857P | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | Fexagratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 N540K | Fexagratinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 K650E | Erdafitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 N540K | Erdafitinib | Advanced Solid Tumor | sensitive | detail... |
BRAF V600E | Lifirafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF wild-type | Lifirafenib | Advanced Solid Tumor | no benefit | detail... |
TP53 mutant | KRT-232 | Advanced Solid Tumor | resistant | detail... |
TP53 wild-type | KRT-232 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152R | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK S1206Y | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174L | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
TP53 positive | p28 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK R1275Q | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
ALK F1174L | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
ALK F1245C | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 mutant | Pemigatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 mutant | Pemigatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 wild-type | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N550K | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 over exp | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650M | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
ATM inact mut | Veliparib | Advanced Solid Tumor | sensitive | detail... |
HRAS G12V | Rigosertib Sodium | Advanced Solid Tumor | sensitive | detail... |
PIK3CA E545K | Rigosertib Sodium | Advanced Solid Tumor | sensitive | detail... |
PIK3CA H1047R | Rigosertib Sodium | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | Lorlatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK I1171S | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171T | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | Lorlatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK G1202del | Crizotinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK G1202del | Ceritinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK G1202del | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202del | Brigatinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK G1202del | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK D1203N | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK E1210K | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK E1210K | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK E1210K | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK E1210K | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C ALK D1203N | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK D1203N | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK D1203N | Brigatinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK F1174C ALK D1203N | Lorlatinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK D1203N ALK E1210K | Crizotinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK D1203N ALK E1210K | Ceritinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK D1203N ALK E1210K | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N ALK E1210K | Brigatinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK D1203N ALK E1210K | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174C ALK D1203N | Ceritinib | Advanced Solid Tumor | resistant | detail... |
KIT D816V | BPR1J373 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 positive | Aprutumab ixadotin | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D835Y | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
ROS1 fusion | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 F691L | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 F691I | Brigatinib | Advanced Solid Tumor | decreased response | detail... |
EML4 - ALK ALK T1151dup | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152R | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152P | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK S1206F | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK S1206Y | Brigatinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK T1151dup | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1152P | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174V | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK L1152R | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1152P | Ceritinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N676D | Midostaurin | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691I | Midostaurin | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691I | Sunitinib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 A848P | Sunitinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691I | Sorafenib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L | Sorafenib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 A848P | Sorafenib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 Y842H | Sorafenib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 N676D | Quizartinib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 Y842H | Quizartinib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 A848P | Quizartinib | Advanced Solid Tumor | decreased response | detail... |
FLT3 exon 14 ins FLT3 F691I | Quizartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L | Quizartinib | Advanced Solid Tumor | resistant | detail... |
TP53 mutant | Adavosertib | Advanced Solid Tumor | predicted - sensitive | detail... |
TSC2 loss | Buthionine sulfoximine + Sirolimus | Advanced Solid Tumor | sensitive | detail... |
BRAF G464E | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF G464V | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF G464R | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF G469A | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF G469V | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF L597V | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF L597Q | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF K601T | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF K601N | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 F691L | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D835Y | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 D835Y | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 D835V | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 Y842H | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 Y842C | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D835F | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D835V | MRX-2843 | Advanced Solid Tumor | sensitive | detail... |
HRAS mutant | Selumetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS mutant | Binimetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS mutant | Everolimus | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS Q61L | Everolimus | Advanced Solid Tumor | sensitive | detail... |
HRAS Q61R | Everolimus | Advanced Solid Tumor | sensitive | detail... |
HRAS G12V | Everolimus | Advanced Solid Tumor | sensitive | detail... |
HRAS Q61R | Binimetinib | Advanced Solid Tumor | sensitive | detail... |
HRAS Q61L | Binimetinib | Advanced Solid Tumor | sensitive | detail... |
HRAS G12V | Binimetinib | Advanced Solid Tumor | sensitive | detail... |
HRAS G12V | Binimetinib + Everolimus | Advanced Solid Tumor | sensitive | detail... |
HRAS Q61L | Binimetinib + Everolimus | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | Tovorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
NRAS G12D | N-Arachidonoyl Dopamine | Advanced Solid Tumor | sensitive | detail... |
HRAS Q61L | NS1 | Advanced Solid Tumor | sensitive | detail... |
NRAS G12D | NS1 | Advanced Solid Tumor | no benefit | detail... |
PTEN inact mut | Capivasertib | Advanced Solid Tumor | sensitive | detail... |
PTEN loss | Capivasertib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Talazoparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Berzosertib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Olaparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Niraparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Rucaparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | Cisplatin + Talazoparib | Advanced Solid Tumor | sensitive | detail... |
IDH1 R132H | AGI-5198 + Talazoparib | Advanced Solid Tumor | decreased response | detail... |
TP53 wild-type | Siremadlin | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 L608V | Infigratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 K650E | Infigratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 N540K | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 V555L | Infigratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 V555M | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 L608V | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 V555M | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 N540K | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | Dovitinib | Advanced Solid Tumor | conflicting | detail... |
FGFR3 N540K | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 V555M | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 L608V | Dovitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 L608V | Fexagratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 V555M | Fexagratinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 L608V | Zoligratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 V555M | Zoligratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 N540K | Zoligratinib | Advanced Solid Tumor | decreased response | detail... |
FGFR3 K650E | Zoligratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 L608V | FIIN-2 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | FIIN-2 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 V555M | FIIN-2 | Advanced Solid Tumor | decreased response | detail... |
FGFR3 N540K | FIIN-2 | Advanced Solid Tumor | decreased response | detail... |
FGFR3 L608V | LY2874455 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 V555M | LY2874455 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650E | LY2874455 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 N540K | LY2874455 | Advanced Solid Tumor | decreased response | detail... |
FGFR2 V564F | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 V564F | Zoligratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 V564F | Fexagratinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 V564I | Zoligratinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 V564L | Zoligratinib | Advanced Solid Tumor | resistant | detail... |
BRAF V600E | PF-00477736 + PF3644022 | Advanced Solid Tumor | predicted - sensitive | detail... |
CDKN2A loss | PF-00477736 + PF3644022 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF mutant | PF-00477736 + PF3644022 | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK rearrange | Belizatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 L115P | CI-1040 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 L115A | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 F53S | CI-1040 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 I103N | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
PTEN loss | Everolimus | Advanced Solid Tumor | no benefit | detail... |
RET C634R RET V804M | Vandetanib | Advanced Solid Tumor | resistant | detail... |
RET C634R RET Y806C | Vandetanib | Advanced Solid Tumor | resistant | detail... |
RET C634R RET Y806E | Vandetanib | Advanced Solid Tumor | resistant | detail... |
RET C634R RET Y806F | Vandetanib | Advanced Solid Tumor | predicted - sensitive | detail... |
TP53 wild-type | MK-8242 | Advanced Solid Tumor | unknown | detail... |
TP53 positive | Serdemetan | Advanced Solid Tumor | sensitive | detail... |
ATM del ATR dec exp | PJ34 | Advanced Solid Tumor | decreased response | detail... |
JAK3 R172Q | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 L156P | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 E183G | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
JAK3 A572V | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | KO-947 | Advanced Solid Tumor | predicted - sensitive | detail... |
NRAS mutant | KO-947 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF mutant | CC-90003 | Advanced Solid Tumor | no benefit | detail... |
NRAS mutant | CC-90003 | Advanced Solid Tumor | no benefit | detail... |
TP53 wild-type | ALRN-6924 | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF F247L | Trametinib | Advanced Solid Tumor | sensitive | detail... |
BRAF F247L | Dabrafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF F595L | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF D594N | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
RAD51D S207L | Olaparib | Advanced Solid Tumor | sensitive | detail... |
RAD51D S207L | Talazoparib | Advanced Solid Tumor | sensitive | detail... |
JAK3 I87T | JANEX-1 | Advanced Solid Tumor | sensitive | detail... |
KIT N822I | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT N822I | Dasatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D | Dasatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Motesanib Diphosphate | Advanced Solid Tumor | sensitive | detail... |
KIT M552_V559del | Motesanib Diphosphate | Advanced Solid Tumor | sensitive | detail... |
KIT Y823D | Motesanib Diphosphate | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT V654A | Motesanib Diphosphate | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT T670I | Motesanib Diphosphate | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Nilotinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Dasatinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT T670I | Dasatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT T670I | Nilotinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT T670I | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT V560del KIT V654A | Nilotinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT D820Y | Nilotinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT D820Y | Dasatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT D820Y | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT exon17 | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
ALK rearrange | ASP3026 | Advanced Solid Tumor | sensitive | detail... |
BRAF V600E/K PTEN loss | PX-866 + Vemurafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK L1198P | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198P | TAE684 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N | TAE684 | Advanced Solid Tumor | resistant | detail... |
HRAS G12V | SR9009 | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS G12V | SR9011 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V561M | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR1 over exp | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 over exp | PRN1371 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290C | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290C | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 S249C | Ponatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 R248C | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 S249C | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 S249C | Dovitinib | Advanced Solid Tumor | conflicting | detail... |
FGFR3 R248C | Dovitinib | Advanced Solid Tumor | conflicting | detail... |
FGFR2 W290C | Pazopanib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Pazopanib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | Pazopanib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 R248C | Pazopanib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290C | Cediranib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Cediranib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | Cediranib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | Fexagratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Fexagratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290C | Fexagratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660E | Lenvatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 K660N | Lenvatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 W290C | Lenvatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 over exp | Derazantinib | Advanced Solid Tumor | sensitive | detail... |
FGFR1 over exp | Derazantinib | Advanced Solid Tumor | sensitive | detail... |
KIT over exp | Derazantinib | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | RAF709 | Advanced Solid Tumor | sensitive | detail... |
NRAS mutant | RAF709 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK I1171T | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK F1174C | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK F1174I | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK F1174V | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK D1203N | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK L1256F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174L ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174V ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1179V ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK L1256F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174C ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171T ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
FGFR1 amp | Fexagratinib | Advanced Solid Tumor | unknown | detail... |
FGFR2 amp | Fexagratinib | Advanced Solid Tumor | unknown | detail... |
ROS1 fusion | Repotrectinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ROS1 fusion ROS1 G2032R | Repotrectinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ALK fusion | Repotrectinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 F53L | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 Q56P | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 K57N | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 C121S | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F129L | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 I111S | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 V211D | Selumetinib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 V211D | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F53L | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 K57N | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 I111S | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 C121S | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 F129L | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 V211D | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F53L | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 Q56P | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 K57N | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 I111S | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 C121S | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F129L | PD98059 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 V211D | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F53L | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 Q56P | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 K57N | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 I111S | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 C121S | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F129L | Regorafenib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 V211D | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F53L | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 Q56P | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 K57N | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 I111S | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 C121S | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F129L | GDC0879 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 V211D | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F53L | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 Q56P | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 K57N | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 I111S | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 C121S | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 F129L | AZD8330 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 Q56P | PLX4720 | Advanced Solid Tumor | sensitive | detail... |
KIT V559D | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559_V560del | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559_V560del | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559_V560del | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Imatinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT V654A | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT T670I | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT N822K | Sunitinib | Advanced Solid Tumor | no benefit | detail... |
KIT V559D KIT Y823D | Sunitinib | Advanced Solid Tumor | no benefit | detail... |
KIT V559D KIT A829P | Sunitinib | Advanced Solid Tumor | no benefit | detail... |
KIT V560D KIT V654A | Flumatinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT T670I | Flumatinib | Advanced Solid Tumor | resistant | detail... |
KIT V559D KIT D820G | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT N822K | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT Y823D | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT I571_D579dup | Sunitinib | Advanced Solid Tumor | predicted - resistant | detail... |
KIT V559D KIT A829P | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT I571_D579dup | Imatinib | Advanced Solid Tumor | predicted - resistant | detail... |
KIT I571_D579dup | Flumatinib | Advanced Solid Tumor | predicted - resistant | detail... |
KIT V559D KIT Y823D | Imatinib | Advanced Solid Tumor | no benefit | detail... |
KIT D816V | Flumatinib | Advanced Solid Tumor | resistant | detail... |
KIT D816Y | Flumatinib | Advanced Solid Tumor | resistant | detail... |
KIT D816Y | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT D816Y | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT D816H | Flumatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT D816H | Sunitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT N822K | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT N822K | Flumatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT N822K | Sunitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT T417_D419delinsI | Flumatinib | Advanced Solid Tumor | sensitive | detail... |
KIT T417_D419delinsI | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
RET M918T | Selpercatinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R T618I | Ibrutinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R Q741* | Ibrutinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R Q741* | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R T618I | Ibrutinib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R Q741* | Ibrutinib + Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
KIT D816F | Imatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Ensartinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R N610H | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R N610S | Ruxolitinib | Advanced Solid Tumor | sensitive | detail... |
CSF3R N610S | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
CSF3R N610H | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V600E | Vemurafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF G596R | Vemurafenib | Advanced Solid Tumor | no benefit | detail... |
BRAF N581S | Vemurafenib | Advanced Solid Tumor | no benefit | detail... |
BRAF G466V | Vemurafenib | Advanced Solid Tumor | no benefit | detail... |
BRAF G606E | Vemurafenib | Advanced Solid Tumor | no benefit | detail... |
BRAF P731T | Vemurafenib | Advanced Solid Tumor | no benefit | detail... |
EML4 - ALK | Repotrectinib | Advanced Solid Tumor | sensitive | detail... |
BRAF N486_T491delinsK | Cobimetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
TP53 mutant | Unspecified VEGFR inhibitor | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D816H | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Iruplinalkib | Advanced Solid Tumor | sensitive | detail... |
FGFR1 amp | Zoligratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 amp | Zoligratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 amp | Zoligratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 fusion | Zoligratinib | Advanced Solid Tumor | no benefit | detail... |
FGFR2 fusion | Zoligratinib | Advanced Solid Tumor | no benefit | detail... |
FGFR3 fusion | Zoligratinib | Advanced Solid Tumor | no benefit | detail... |
FGFR1 mutant | Zoligratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 mutant | Zoligratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 mutant | Zoligratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
ATM negative | Elimusertib | Advanced Solid Tumor | predicted - sensitive | detail... |
ATM inact mut | Elimusertib | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF mutant | LXH 254 | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 V211D | Binimetinib | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 V211D | Cobimetinib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V504_R506dup | Sorafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF V504_R506dup | Vemurafenib | Advanced Solid Tumor | resistant | detail... |
BRAF V504_R506dup | Trametinib | Advanced Solid Tumor | sensitive | detail... |
KIT L576P | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559A | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559G | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V559D KIT V654A | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT A829P | Axitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
BRAF mut TP53 wild-type | Pimasertib + SAR405838 | Advanced Solid Tumor | predicted - sensitive | detail... |
NRAS mut TP53 wild-type | Pimasertib + SAR405838 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK S1206Y | Alectinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK T1151dup | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1152R | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1152R | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | ASP3026 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1202R | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK S1206Y | ASP3026 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK S1206Y | Crizotinib | Advanced Solid Tumor | resistant | detail... |
PIK3CA H1047R | Alpelisib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT V654A KIT D816V | Midostaurin | Advanced Solid Tumor | resistant | detail... |
KIT T670I KIT D816V | Midostaurin | Advanced Solid Tumor | decreased response | detail... |
KIT N655K KIT D816V | Midostaurin | Advanced Solid Tumor | resistant | detail... |
KIT Y672C KIT D816V | Midostaurin | Advanced Solid Tumor | decreased response | detail... |
KIT D677N KIT D816V | Midostaurin | Advanced Solid Tumor | resistant | detail... |
KIT D816V | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
KIT D816V | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT V654A KIT D816V | Avapritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT N655K KIT D816V | Avapritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT Y672C KIT D816V | Avapritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT D677N KIT D816V | Avapritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT T670I KIT D816V | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT T670A KIT D816V | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670V KIT D816V | Avapritinib | Advanced Solid Tumor | predicted - resistant | detail... |
KIT T670A KIT D816V | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
KIT T670V KIT D816V | Midostaurin | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT V654A | Avapritinib | Advanced Solid Tumor | decreased response | detail... |
KIT D816V | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT D816V | Regorafenib | Advanced Solid Tumor | resistant | detail... |
PIK3CA mutant | Alpelisib + Infigratinib | Advanced Solid Tumor | no benefit | detail... |
HRAS G12V | WM-8014 | Advanced Solid Tumor | sensitive | detail... |
SMARCB1 negative | Tazemetostat | Advanced Solid Tumor | predicted - sensitive | detail... |
SMARCA4 negative | Tazemetostat | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V600X | Dabrafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
FLT3 exon 14 ins | LAM-003 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 F691L | LAM-003 | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins | Crenolanib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK C1156Y ALK G1269A | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174L ALK G1202R | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 R971G | Ruxolitinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 L983F | Ruxolitinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 E987D | Ruxolitinib | Advanced Solid Tumor | resistant | detail... |
TP53 R181E | Nutlin-3a | Advanced Solid Tumor | no benefit | detail... |
TP53 R181E | Doxorubicin + Nutlin-3a | Advanced Solid Tumor | sensitive | detail... |
TP53 R181E | Doxorubicin + SAR405838 | Advanced Solid Tumor | sensitive | detail... |
TP53 R181E | Doxorubicin + Idasanutlin | Advanced Solid Tumor | sensitive | detail... |
TP53 R181E | Doxorubicin + RG7112 | Advanced Solid Tumor | sensitive | detail... |
JAK2 V617F JAK2 Y931C | Fedratinib | Advanced Solid Tumor | sensitive | detail... |
JAK2 V617F JAK2 Y931C JAK2 S1025C | Fedratinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 Y931C JAK2 Y1045W | Fedratinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 Y931C JAK2 F1061W | Fedratinib | Advanced Solid Tumor | resistant | detail... |
JAK2 V617F JAK2 Y931C JAK2 V1075F | Fedratinib | Advanced Solid Tumor | resistant | detail... |
BRAF mutant | LY3009120 | Advanced Solid Tumor | no benefit | detail... |
NRAS mutant | LY3009120 | Advanced Solid Tumor | no benefit | detail... |
EML4 - ALK | Taletrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
RET R886W | Sorafenib | Advanced Solid Tumor | sensitive | detail... |
BRAF mutant | Trametinib | Advanced Solid Tumor | no benefit | detail... |
BRAF G466V | Trametinib | Advanced Solid Tumor | no benefit | detail... |
RET fusion | Pralsetinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 act mut | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 act mut | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171T | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269S | TPX-0131 | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M ALK L1198F | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK L1198F | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y ALK G1202R | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1202R | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R ALK G1269A | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R ALK L1204V ALK G1269A | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1202R ALK G1269A | TPX-0131 | Advanced Solid Tumor | sensitive | detail... |
KIT C809G | Imatinib | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 E41_L54del | Trametinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 E41_L54del | Selumetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 E41_L54del | Cobimetinib | Advanced Solid Tumor | sensitive | detail... |
MAP2K1 E41_L54del | LY3009120 | Advanced Solid Tumor | no benefit | detail... |
JAK3 T1022I | Tofacitinib | Advanced Solid Tumor | sensitive | detail... |
FLT3 exon 14 ins FLT3 D698N | Gilteritinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N676T | Quizartinib | Advanced Solid Tumor | resistant | detail... |
FLT3 exon 14 ins FLT3 N676T | Midostaurin | Advanced Solid Tumor | resistant | detail... |
ATM inact mut | Radiotherapy | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF V600X | Lifirafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT W557_K558del KIT V654A | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT V654A | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT V654A | Ripretinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT T670I | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT V654A | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT V654A | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT V654A | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT V654A | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT V654A | Ripretinib | Advanced Solid Tumor | decreased response | detail... |
KIT A502_Y503dup KIT V654A | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup KIT V654A | Sunitinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup KIT V654A | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT V654A | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT V654A | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT V654A | Ripretinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT T670I | Avapritinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT T670I | Ripretinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT D816H | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D816H | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT N822K | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT N822K | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT N822K | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D820A | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D820A | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT D820A | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT Y823D | Ripretinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT Y823D | Regorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT W557_K558del KIT Y823D | Avapritinib | Advanced Solid Tumor | decreased response | detail... |
KIT W557_K558del KIT Y823D | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT Y823D | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT W557_K558del KIT Y823D | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT A829P | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT A829P | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT W557_K558del KIT A829P | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT D816H | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT D816H | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT D816H | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT D816H | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT D820A | Avapritinib | Advanced Solid Tumor | decreased response | detail... |
KIT V560D KIT D816H | Avapritinib | Advanced Solid Tumor | decreased response | detail... |
KIT V560D KIT D816H | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT D820A | Ripretinib | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT D820A | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT V560D KIT D820A | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT D820A | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT V560D KIT D820A | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup KIT D816H | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT D816H | Sunitinib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT D816H | Regorafenib | Advanced Solid Tumor | resistant | detail... |
KIT A502_Y503dup KIT D816H | AZD3229 | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup KIT D816H | Avapritinib | Advanced Solid Tumor | sensitive | detail... |
KIT A502_Y503dup KIT D816H | Ripretinib | Advanced Solid Tumor | decreased response | detail... |
FGFR1 over exp | Rogaratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 over exp | Rogaratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 over exp | Rogaratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH1 R132L | DS-1001b | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH1 R132G | DS-1001b | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH1 R132S | DS-1001b | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH1 R132C | DS-1001b | Advanced Solid Tumor | predicted - sensitive | detail... |
IDH1 R132H | DS-1001b | Advanced Solid Tumor | predicted - sensitive | detail... |
HRAS G12V HRAS R135K | NS1 | Advanced Solid Tumor | resistant | detail... |
HRAS G12V HRAS R135A | NS1 | Advanced Solid Tumor | resistant | detail... |
KIT wild-type | PLX9486 | Advanced Solid Tumor | sensitive | detail... |
KIT D816V | PLX9486 | Advanced Solid Tumor | sensitive | detail... |
KIT V560G KIT D816V | Imatinib | Advanced Solid Tumor | resistant | detail... |
KIT V560G KIT D816V | PLX9486 | Advanced Solid Tumor | sensitive | detail... |
PIK3CA act mut | Palbociclib + Taselisib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT W557_K558del | Cabozantinib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Regorafenib | Advanced Solid Tumor | sensitive | detail... |
KIT T670I | Cabozantinib | Advanced Solid Tumor | sensitive | detail... |
KIT N655K | Imatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT N655K | Sunitinib | Advanced Solid Tumor | decreased response | detail... |
KIT N655K | Regorafenib | Advanced Solid Tumor | decreased response | detail... |
KIT N655K | Cabozantinib | Advanced Solid Tumor | decreased response | detail... |
KIT N655K | Avapritinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT N655K | Ripretinib | Advanced Solid Tumor | predicted - sensitive | detail... |
KIT T670I | Imatinib | Advanced Solid Tumor | resistant | detail... |
BRAF V600E | Trametinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 fusion | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 amp | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 amp | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171T | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171T | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171S | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK C1156Y | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK T1151K | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK V1180L | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK V1180L | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK F1174V | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174I | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1174V | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1174I | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1198F | Entrectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196Q | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196Q | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196Q | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196Q | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196Q | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196Q | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196Q | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1202R | Gilteritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N | Gilteritinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK F1245V | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245V | Crizotinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245V | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245V | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245V | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK F1245V | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK F1245V | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1256F | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1256F | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1256F | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1256F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1256F | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1256F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1256F | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK G1269A | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174I | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK F1174L | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Crizotinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Crizotinib | Advanced Solid Tumor | conflicting | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Brigatinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Entrectinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1198F | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1198H | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1196M | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171S ALK G1269A | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Ceritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK G1269A | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Lorlatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK I1171N ALK L1256F | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Gilteritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Brigatinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK G1202R | Ceritinib | Advanced Solid Tumor | resistant | detail... |
RET over exp | Cabozantinib | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1198F ALK G1202R | Gilteritinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Brigatinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Gilteritinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Alectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK L1196M ALK D1203N | Ceritinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Ceritinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Lorlatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Entrectinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Gilteritinib | Advanced Solid Tumor | predicted - resistant | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Alectinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Brigatinib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK D1203N ALK F1245V | Crizotinib | Advanced Solid Tumor | resistant | detail... |
PIK3CA act mut | TAS-117 | Advanced Solid Tumor | no benefit | detail... |
PIK3CA act mut | LY3023414 + Prexasertib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 mutant | ICP-192 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 mutant | ICP-192 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 mutant | ICP-192 | Advanced Solid Tumor | predicted - sensitive | detail... |
TP53 Y220C | PC14586 | Advanced Solid Tumor | predicted - sensitive | detail... |
TSC1 inact mut | Nab-rapamycin | Advanced Solid Tumor | predicted - sensitive | detail... |
TSC2 inact mut | Nab-rapamycin | Advanced Solid Tumor | predicted - sensitive | detail... |
BRAF mutant | Binimetinib + Encorafenib | Advanced Solid Tumor | predicted - sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | Advanced Solid Tumor | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | Advanced Solid Tumor | sensitive | detail... |
NRAS act mut | Selumetinib | Advanced Solid Tumor | no benefit | detail... |
HRAS act mut | Selumetinib | Advanced Solid Tumor | no benefit | detail... |
BRAF V600E | Selumetinib | Advanced Solid Tumor | no benefit | detail... |
RET V804M RET M918T | Selpercatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
RET V804M RET G810C RET M918T | Selpercatinib | Advanced Solid Tumor | resistant | detail... |
RET V804M RET G810S RET M918T | Selpercatinib | Advanced Solid Tumor | resistant | detail... |
NRAS G12X | Binimetinib | Advanced Solid Tumor | no benefit | detail... |
NRAS G13X | Binimetinib | Advanced Solid Tumor | no benefit | detail... |
NRAS Q61X | Binimetinib | Advanced Solid Tumor | unknown | detail... |
RB1 positive | Dalpiciclib | Advanced Solid Tumor | sensitive | detail... |
RB1 dec exp | Dalpiciclib | Advanced Solid Tumor | no benefit | detail... |
NRAS Q61R | Belvarafenib | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK ALK G1269S | Crizotinib | Advanced Solid Tumor | resistant | detail... |
EML4 - ALK ALK S1206R | Crizotinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549H | E7090 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549H | Futibatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549K | Fexagratinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549K | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549K | Erdafitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549K | Pemigatinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549K | E7090 | Advanced Solid Tumor | conflicting | detail... |
FGFR2 N549D | Fexagratinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549D | Infigratinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549D | Erdafitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549D | Futibatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549D | Pemigatinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 K650N | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650N | E7090 | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650N | Erdafitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650N | Futibatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR3 K650N | Pemigatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549K | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR2 N549D | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 K650T | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 K650M | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR3 K650M | Fexagratinib | Advanced Solid Tumor | resistant | detail... |
FGFR1 N546K | Fexagratinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 N546K | Infigratinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 N546K | Erdafitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 N546K | Futibatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 N546K | Pemigatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 N546K | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 N549S | Infigratinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549S | E7090 | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549S | Erdafitinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549S | Futibatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549S | Pemigatinib | Advanced Solid Tumor | sensitive | detail... |
FGFR2 N549S | Dovitinib | Advanced Solid Tumor | resistant | detail... |
FGFR1 K656E | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 K656E | Pemigatinib | Advanced Solid Tumor | conflicting | detail... |
FGFR1 K656E | Erdafitinib | Advanced Solid Tumor | conflicting | detail... |
FGFR1 K656E | Infigratinib | Advanced Solid Tumor | conflicting | detail... |
FGFR1 K656M | Fexagratinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 K656M | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 K656M | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 S252W | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S252W | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S252W | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S252W | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S252W | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 S252W | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 Y375C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 C382R | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C382R | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C382R | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C382R | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C382R | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C382R | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 K659E | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659E | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659E | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659E | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 K659N | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 K659N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659N | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659N | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 K659N | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 S249C | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 G370C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 G370C | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 G370C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 S371C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 S371C | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 S371C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 Y373C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 Y373C | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 Y373C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380R | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380R | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380R | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 G380R | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR3 A391E | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 A391E | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 A391E | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 A391E | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR3 A391E | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490del | Vemurafenib | Advanced Solid Tumor | predicted - resistant | detail... |
BRAF L485_P490del | LY3009120 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 V564M | Infigratinib | Advanced Solid Tumor | resistant | detail... |
MLH1 negative | Pembrolizumab | Advanced Solid Tumor | sensitive | detail... |
MSH6 negative | Pembrolizumab | Advanced Solid Tumor | sensitive | detail... |
FGFR1 S125L | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S125L | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 T141R | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T141R | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T141R | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T141R | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T141R | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T141R | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P150S | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P150S | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P150S | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P150S | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R250W | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A268S | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A268S | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A268S | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 A268S | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A268S | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 L98_K104delinsQ | Trametinib | Advanced Solid Tumor | resistant | detail... |
MAP2K1 L98_K104delinsQ | MK2206 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 L98_K104delinsQ | U0126 | Advanced Solid Tumor | resistant | detail... |
MAP2K1 L98_K104delinsQ | SCH772984 | Advanced Solid Tumor | resistant | detail... |
FGFR1 A21T | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A21T | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A21T | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A21T | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A21T | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A21T | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Dovitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T26I | Fexagratinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 A121D | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 A121D | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 D128N | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128N | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D128V | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D133N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R189C | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R189C | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R189C | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 S238N | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 S238N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S238N | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S238N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S238N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S238N | Infigratinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 S238N | Fexagratinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 T319A | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T319A | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T319A | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 T319A | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T319A | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T319A | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 D320N | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D320N | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D320N | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D320N | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D320N | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 D320N | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 T340M | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S436F | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S436F | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S436F | E7090 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 S436F | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S436F | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S436F | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA act mut | Docetaxel + Ipatasertib | Advanced Solid Tumor | predicted - sensitive | detail... |
PIK3CA act mut | Fluorouracil + Ipatasertib + Leucovorin + Oxaliplatin | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R445W | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R445W | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R445W | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R445W | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R445W | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 M456V | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 M456V | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E467K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 G703S | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 G703S | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 G703S | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 G703S | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 G703S | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E592G | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E592G | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E592G | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E592G | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 E592G | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S588T | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S588T | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S588T | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S588T | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 S588T | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R475Q | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R475Q | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R475Q | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R475Q | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P483L | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P483L | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P483L | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P483L | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 P483L | Futibatinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR1 P483L | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
RET M918T | LOX-18228 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK L1196M ALK G1202R | NVL-655 | Advanced Solid Tumor | sensitive | detail... |
EML4 - ALK | NVL-655 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK G1202R | NVL-655 | Advanced Solid Tumor | predicted - sensitive | detail... |
EML4 - ALK ALK G1202R ALK G1269A | NVL-655 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 V751A | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR1 R809Q | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 R6P | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 L33S | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 L33S | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
MAP2K1 I111A | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 I111D | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 I111P | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 I111R | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 I139G | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 I139R | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 I139N | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 L118G | CI-1040 | Advanced Solid Tumor | decreased response | detail... |
MAP2K1 L118Q | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 L118P | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
MAP2K1 L118D | CI-1040 | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 L33S | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L33S | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L33S | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L33S | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 L33S | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 C62Y | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 A67V | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A67V | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A67V | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A67V | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A67V | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 A67V | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 N82K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 D101Y | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 E160K | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 E160K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E160K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E160K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E160K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E160K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E160K | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 E163K | Dovitinib | Advanced Solid Tumor | predicted - resistant | detail... |
FGFR2 M186T | Fexagratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | Infigratinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | E7090 | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | Erdafitinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | Futibatinib | Advanced Solid Tumor | predicted - sensitive | detail... |
FGFR2 M186T | Pemigatinib | Advanced Solid Tumor | predicted - sensitive | detail... |